Mar Vista Investment Partners, LLC, an investment management company, released its “Mar Vista U.S. Quality Strategy” first-quarter 2026 investor letter. A copy of the letter can be downloaded here. U.S. equities entered 2026 with sustained momentum, despite market leadership evolving significantly over the first quarter. Initial support in equities was hampered by tariff uncertainty, doubts about AI-driven growth sustainability, and emerging private credit concerns, before geopolitical challenges. The quarter saw the lowest performance for U.S. equities in this volatile environment, influenced by rising oil prices due to the Middle East conflict, altering inflation and interest rate expectations. The Mar Vista U.S. Quality strategy returned -7.24% net-of-fees in the quarter vs Russell 1000® Index’s -4.18% and the S&P 500® Index’s -4.33% returns. The firm believes the market is transitioning towards high-quality businesses with strong competitive advantages. Please review the Strategy’s top five holdings to gain insights into their key selections for 2026.
In its first-quarter 2026 investor letter, Mar Vista U.S. Quality Strategy highlighted Johnson & Johnson (NYSE:JNJ). Johnson & Johnson (NYSE:JNJ) is a leading global healthcare company that engages in the research and development, manufacture, and sale of a range of products in the healthcare field. On April 10, 2026, Johnson & Johnson (NYSE:JNJ) closed at $238.46 per share. One-month return of Johnson & Johnson (NYSE:JNJ) was -1.94%, and its shares gained 54.48% over the past 52 weeks. Johnson & Johnson (NYSE:JNJ) has a market capitalization of $574.36 billion.
Mar Vista U.S. Quality Strategy stated the following regarding Johnson & Johnson (NYSE:JNJ) in its Q1 2026 investor letter:
“Johnson & Johnson (NYSE:JNJ) appreciated 18.74% during the first quarter driven by strong Innovative Medicine growth, improved outlook for the medical device segment, and management’s comment that there is a “line of sight” to double-digit revenue growth by the end of the decade. JNJ’s Innovative Medicine segment continues to provide results that exceed expectations. Rapidly growing products in oncology and immunology, combined with a solid pipeline of new candidates, has changed investors’ narrative on JNJ’s pharma business from one of patent risk to pipeline durability. In MedTech, the company is reallocating capital from low-growth businesses, like Orthopaedics, and toward higher-growth segments, particularly cardiovascular and electrophysiology. Enthusiasm is also rising for JNJ’s imminent entry into the robotic surgery market. Despite the stock’s appreciation over the last year, JNJ remains one of the few large-cap healthcare stocks offering a combination of defensive characteristics, accelerating growth and consensus expectations that are still below management’s long-term guidance.”
Johnson & Johnson (NYSE:JNJ) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 104 hedge fund portfolios held Johnson & Johnson (NYSE:JNJ) at the end of the fourth quarter, up from 103 in the previous quarter. While we acknowledge the risk and potential of Johnson & Johnson (NYSE:JNJ) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than Johnson & Johnson (NYSE:JNJ) and that has 10,000% upside potential, check out our report about this cheapest AI stock.
In another article, we covered Johnson & Johnson (NYSE:JNJ) and shared the list of best low volatility blue chip stocks to buy. In addition, please check out our hedge fund investor letters Q1 2026 page for more investor letters from hedge funds and other leading investors.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. This article is originally published at Insider Monkey.
